Bolt Biotherapeutics Inc
Bolt Biotherapeutics Inc
BOLT

Bolt Biotherapeutics Inc (BOLT)

$2.042%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.86
Day's Range
$2.07
$1.39
52-Week Range
$19.29
1 month return17.65%
3 month return29.08%
1 year return86.01%
5 year return93.78%

Company Information

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response in the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to target tumor cells for elimination by myeloid cells, which are then activated and recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products.
OrganizationBolt Biotherapeutics Inc
Employees65
CEO

Analyst Recommendation

based on 11 analysts ratings

Buy
81%
Buy
18%
Hold
0%
Sell

Based on 11 Wall street analysts offering stock ratings for Bolt Biotherapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 450.0%

Current

$2.0

Target

$11.0

Recommendation Trend

Based on 11 analyst

Current1M Ago3M Ago
Buy
9
10
10
Hold
2
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
62.6M
Book Value
7.38
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-4.2
Wall Street Target Price
17.2

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
83.2
Price/Book (mrq)
0.28
Enterprise Value
-92551323
Enterprise Value/Revenue
270.65
Enterprise Value/Ebitda
1.01

Technicals

50 Day MA
2.81
200 Day MA
8.23

Institutional Holdings

Novo A/S

12.02%

Vivo Capital, LLC

10.33%

Citadel Advisors Llc

7.51%

Sofinnova Ventures

7.35%

RA Capital Management, LLC

6.35%

Suvretta Capital Management, LLC

5.95%

Discover more

Frequently Asked Questions

What is Bolt Biotherapeutics Inc share price today?

Can Indians buy Bolt Biotherapeutics Inc shares?

How can I buy Bolt Biotherapeutics Inc shares from India?

Can Fractional shares of Bolt Biotherapeutics Inc be purchased?

What are the documents required to start investing in Bolt Biotherapeutics Inc stocks?

What are today’s High and Low prices of Bolt Biotherapeutics Inc?

What are today’s traded volumes of Bolt Biotherapeutics Inc?

What is today’s market capitalisation of Bolt Biotherapeutics Inc?

What is the 52 Week High and Low Range of Bolt Biotherapeutics Inc?

How much percentage Bolt Biotherapeutics Inc is down from its 52 Week High?

How much percentage Bolt Biotherapeutics Inc is up from its 52 Week low?

What are the historical returns of Bolt Biotherapeutics Inc?

Who is the Chief Executive Officer (CEO) of Bolt Biotherapeutics Inc?